VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM), a late stage cancer company, announced today that Geert Kersten, Chief Executive Officer, will be presenting an overview of the upcoming Phase III clinical trial with the Company’s cancer immunotherapy product Multikine® at the Rodman & Renshaw Annual Global Healthcare Conference. The conference will take place May 16-18 at the Grosvenor House Hotel in London, UK.
